CN110475572A - 基于hdac抑制剂的抗体药物缀合物(adc)和在疗法中的用途 - Google Patents

基于hdac抑制剂的抗体药物缀合物(adc)和在疗法中的用途 Download PDF

Info

Publication number
CN110475572A
CN110475572A CN201880022128.4A CN201880022128A CN110475572A CN 110475572 A CN110475572 A CN 110475572A CN 201880022128 A CN201880022128 A CN 201880022128A CN 110475572 A CN110475572 A CN 110475572A
Authority
CN
China
Prior art keywords
antibody
cancer
drug
mmol
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880022128.4A
Other languages
English (en)
Chinese (zh)
Inventor
L·韦希
R·德桑蒂斯
F·M·米拉佐
G·詹尼尼
M·塔迪
V·法尔托尼
E·佩特里奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfa Sigma Co Ltd
Original Assignee
Alfa Sigma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Sigma Co Ltd filed Critical Alfa Sigma Co Ltd
Publication of CN110475572A publication Critical patent/CN110475572A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201880022128.4A 2017-03-27 2018-03-27 基于hdac抑制剂的抗体药物缀合物(adc)和在疗法中的用途 Pending CN110475572A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17163065.0 2017-03-27
EP17163065.0A EP3381474A1 (en) 2017-03-27 2017-03-27 Histone deacetylase inhibitors-based antibody drug conjugates (adcs) and use in therapy
PCT/EP2018/057744 WO2018178060A1 (en) 2017-03-27 2018-03-27 HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY

Publications (1)

Publication Number Publication Date
CN110475572A true CN110475572A (zh) 2019-11-19

Family

ID=58448395

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880022128.4A Pending CN110475572A (zh) 2017-03-27 2018-03-27 基于hdac抑制剂的抗体药物缀合物(adc)和在疗法中的用途

Country Status (15)

Country Link
US (1) US20210128740A1 (https=)
EP (2) EP3381474A1 (https=)
JP (1) JP2020515578A (https=)
KR (1) KR20190126824A (https=)
CN (1) CN110475572A (https=)
AU (1) AU2018241840A1 (https=)
BR (1) BR112019013449A2 (https=)
CA (1) CA3047359A1 (https=)
EA (1) EA201991985A1 (https=)
IL (1) IL268821A (https=)
MX (1) MX2019011492A (https=)
SG (2) SG10202109654SA (https=)
TN (1) TN2019000187A1 (https=)
UA (1) UA125311C2 (https=)
WO (1) WO2018178060A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023061405A1 (zh) * 2021-10-12 2023-04-20 成都科岭源医药技术有限公司 一种高稳定性的靶向接头-药物偶联物
CN118085013A (zh) * 2022-11-25 2024-05-28 成都微芯新域生物技术有限公司 一种连接子、含连接子的抗体药物偶联物及其制备方法和应用
WO2025011398A1 (zh) * 2023-07-11 2025-01-16 南京市鸿舜医药科技有限公司 一种组蛋白去乙酰化酶抑制剂及用途
WO2025228384A1 (en) * 2024-04-30 2025-11-06 Hutchmed Limited Antibody-drug conjugates and use thereof

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3930746A4 (en) 2019-02-25 2023-03-15 Emory University CHIMERA COMPOUNDS AND METHODS FOR MANAGEMENT OF NEUROLOGICAL DISORDERS OR CONDITIONS
AU2020380333A1 (en) * 2019-11-06 2022-04-07 Dana-Farber Cancer Institute, Inc. Selective histone deacetylase (HDAC) degraders and methods of use thereof
EP4183781A4 (en) * 2020-07-20 2024-01-03 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Sulfur-containing isoindoline derivative, and preparation method therefor and medical use thereof
CN112430229B (zh) * 2020-11-24 2023-03-21 福建医科大学 一种靶向降解parp蛋白的化合物及其制备方法与应用
CN113292465B (zh) * 2021-06-17 2022-11-08 贵州医科大学 一种半胱氨酸衍生物及其合成方法、应用
WO2023059581A1 (en) * 2021-10-04 2023-04-13 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and their use in treating disease
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202543650A (zh) 2024-03-08 2025-11-16 美商海爾達醫療運營公司 異雙官能化合物及其在治療疾病中之用途
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
CN121401440A (zh) * 2025-10-21 2026-01-27 北京晟日昭阳生物科技有限公司 一种靶向治疗胰腺癌的抗体偶联物及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1993146A (zh) * 2004-06-01 2007-07-04 健泰科生物技术公司 抗体－药物偶联物和方法
US20140348823A1 (en) * 2005-11-10 2014-11-27 Topotarget Uk Limited Histone Deacetylase (HDAC) Inhibitors for the Treatment of Cancer
WO2015157595A1 (en) * 2014-04-11 2015-10-15 Medimmune, Llc Conjugated compounds comprising cysteine-engineered antibodies
CN105451775A (zh) * 2013-05-31 2016-03-30 法马马有限公司 药物抗体缀合物
CN105473616A (zh) * 2013-07-05 2016-04-06 形成生物产品有限公司 Egfr抗体缀合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2276506A4 (en) * 2008-04-30 2014-05-07 Immunogen Inc EFFICIENT CONJUGATES AND HYDROPHILIC BINDER

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1993146A (zh) * 2004-06-01 2007-07-04 健泰科生物技术公司 抗体－药物偶联物和方法
US20140348823A1 (en) * 2005-11-10 2014-11-27 Topotarget Uk Limited Histone Deacetylase (HDAC) Inhibitors for the Treatment of Cancer
CN105451775A (zh) * 2013-05-31 2016-03-30 法马马有限公司 药物抗体缀合物
CN105473616A (zh) * 2013-07-05 2016-04-06 形成生物产品有限公司 Egfr抗体缀合物
WO2015157595A1 (en) * 2014-04-11 2015-10-15 Medimmune, Llc Conjugated compounds comprising cysteine-engineered antibodies

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ALISA J.CHRISTIANSEN等: "Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies", 《PROC NATL ACAD SCI U S A》 *
GIANFRANCO BATTISTUZZI等: "Syntheses of ST7612AA1，a Novel Oral HDAC Inhibitor，via Radical Thioacetic Acid Addition", 《CURRENT BIOACTIVE COMPOUNDS》 *
THOMAS H.PILLOW等: "Site-specific Trastuzumab Maytansinoid Antibody-Drug Conjugates with Improved Therapeutic Activity through Linker and Antibody Engineering", 《JOURNAL OF MEDICINAL CHEMISTRY》 *
彭司勋主编: "《药物化学进展》", 31 July 2007, 化学工业出版社 *
王彦明等: "美登素类抗体药物偶联研究进展", 《国际药学研究杂志》 *
黄强等: "组蛋白去乙酰化酶抑制剂在肿瘤治疗领域的进展", 《西南军医》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023061405A1 (zh) * 2021-10-12 2023-04-20 成都科岭源医药技术有限公司 一种高稳定性的靶向接头-药物偶联物
CN118085013A (zh) * 2022-11-25 2024-05-28 成都微芯新域生物技术有限公司 一种连接子、含连接子的抗体药物偶联物及其制备方法和应用
WO2024109928A1 (zh) * 2022-11-25 2024-05-30 成都微芯新域生物技术有限公司 一种连接子、含连接子的抗体药物偶联物及其制备方法和应用
CN118085013B (zh) * 2022-11-25 2025-08-29 成都微芯新域生物技术有限公司 一种连接子、含连接子的抗体药物偶联物及其制备方法和应用
WO2025011398A1 (zh) * 2023-07-11 2025-01-16 南京市鸿舜医药科技有限公司 一种组蛋白去乙酰化酶抑制剂及用途
WO2025228384A1 (en) * 2024-04-30 2025-11-06 Hutchmed Limited Antibody-drug conjugates and use thereof

Also Published As

Publication number Publication date
KR20190126824A (ko) 2019-11-12
CA3047359A1 (en) 2018-10-04
MX2019011492A (es) 2019-11-01
SG11201906543RA (en) 2019-08-27
UA125311C2 (uk) 2022-02-16
US20210128740A1 (en) 2021-05-06
TN2019000187A1 (en) 2020-10-05
BR112019013449A2 (pt) 2019-12-31
EP3600444A1 (en) 2020-02-05
EA201991985A1 (ru) 2020-02-25
WO2018178060A1 (en) 2018-10-04
JP2020515578A (ja) 2020-05-28
IL268821A (en) 2019-10-31
SG10202109654SA (en) 2021-10-28
AU2018241840A1 (en) 2019-10-03
EP3381474A1 (en) 2018-10-03

Similar Documents

Publication Publication Date Title
CN110475572A (zh) 基于hdac抑制剂的抗体药物缀合物(adc)和在疗法中的用途
JP7843731B2 (ja) ビス－オクタヒドロフェナントレンカルボキサミド及びそのタンパク質コンジュゲート
CN105636591B (zh) 配体-细胞毒性药物偶联物、其制备方法及其应用
WO2021249228A1 (zh) 一种带有高稳定性亲水连接单元的喜树碱类药物及其偶联物
CN118414339A (zh) 一种喜树碱类化合物及其偶联物
TW201620554A (zh) 抗ｈｅｒ２抗體－藥物結合物
WO2020035027A1 (zh) 连接子、含连接子的抗体偶联药物及连接子的用途
WO2023083381A1 (zh) 双特异性抗体-喜树碱类药物偶联物及其医药用途
CN107922457A (zh) 用于控制药物释放的递送系统
JP2022516427A (ja) ツブリシン及びタンパク質－ツブリシンコンジュゲート
WO2018192407A1 (zh) 细胞毒素和偶联物、其用途和制备方法
WO2024175069A1 (zh) 喜树碱衍生物及其偶联物以及其制备方法和医药用途
WO2025011419A1 (zh) 一种连接子-药物分子及抗体药物偶联物、其制备方法和应用
WO2024153149A1 (zh) 一种抗体药物偶联物、制备方法及其应用
CN112601556B (zh) 含有芳硝基的连接子、含连接子的抗体偶联药物及连接子的用途
WO2023098889A1 (zh) 抗人Trop2抗体-喜树碱类药物偶联物及其医药用途
EA042689B1 (ru) Конъюгаты антитело-лекарственное средство (калс) на основе ингибиторов гдац и применение в терапии
WO2026067713A1 (zh) 抗体药物偶联物，及其制备方法和用途
WO2025113553A1 (zh) 含有偶氮苯的连接子、含连接子的蛋白偶联药物及其医药用途
TW202408582A (zh) 新穎的澳瑞他汀前藥
TW202532076A (zh) 抗claudin18.2抗體-喜樹鹼藥物偶聯物及其醫藥用途
HK40120540A (zh) 一种连接子-药物分子及抗体药物偶联物、其制备方法和应用
HK40123191B (zh) 喜树硷衍生物及其偶联物以及其制备方法和医药用途
HK1223562B (zh) 配体-细胞毒性药物偶联物、其制备方法及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191119

WD01 Invention patent application deemed withdrawn after publication